• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD. IMMULITE® 2000 CEA; SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD. IMMULITE® 2000 CEA; SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN Back to Search Results
Model Number N/A
Medical Device Problem Code High Test Results (2457)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 03/13/2023
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
An outside united states (ous) customer contacted a siemens customer care center to report falsely elevated cea results that were obtained on samples from two patients on an immulite 2000 xpi instrument and considered discordant with the lower repeat results.The ifu states in the limitations section: ¿patients with confirmed carcinoma often have pretreatment cea levels in the same range as healthy persons.Elevated cea levels are frequently observed in smokers, in cancer patients and in patients with a variety of nonmalignant diseases and inflammatory conditions.Therefore, a serum cea level, regardless of its value, should not be interpreted as absolute evidence for the presence or absence of malignant disease.The cea value should be used in conjunction with information available from clinical evaluation and other diagnostic procedures.The immulite 2000 cea assay should not be used as a cancer screening test.¿ siemens healthcare diagnostics is investigating.
 
Event or Problem Description
Falsely elevated cea (carcinoembryonic antigen) results were obtained on samples from two patients on an immulite 2000 xpi instrument and considered discordant with the lower repeat results.There are no known reports of patient intervention or adverse health consequences due to the falsely elevated cea results.
 
Additional Manufacturer Narrative
Siemens filed the initial mdr 2432235-2023-00133 on (b)(6) 2023.An outside united states (ous) customer contacted a siemens customer care center to report falsely elevated cea results that were obtained on samples from two patients on an immulite 2000 xpi instrument and considered discordant with the lower repeat results.June 04, 2023 additional information: siemens investigated.The customer provided the 2 patient samples that had nonrepeatable elevated results when using the immulite 2000 xpi cea assay for further testing.Siemens performed internal testing of these samples with the immulite 2000 xpi cea kit lot 365 along with 5 in house serum normal patient samples.Each sample was tested in replicates of 10 and none of the samples tested internally by siemens had nonrepeatable elevated results.In summary, there is no indication the issue with nonrepeatable elevated results is due to immulite 2000 xpi cea reagents.This testing does not rule out an integrity issue with the customer's samples when they were originally tested because the integrity of the samples may have changed over time (fibrin in the sample may have broken down over, particulate matter in the sample may have settled out, etc.).Based on the available information, the cause of the discordant results is consistent with sample integrity issues.No further evaluation of the device is required.In section h6, the investigation finding and investigation conclusion codes were updated.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMMULITE® 2000 CEA
Common Device Name
SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD.
glyn rhonwy
llanberis, gwynedd LL55 4EL
UK  LL55 4EL
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED
glyn rhonwy
uk registration #: 3002806944
llanberis, gwynedd LL55 4EL
UK   LL55 4EL
Manufacturer Contact
eiman sulieman
511 benedict ave.
tarrytown, NY 10591
7372808688
MDR Report Key17050071
Report Number2432235-2023-00133
Device Sequence Number7040041
Product Code DHX
UDI-Device Identifier00630414961125
UDI-Public00630414961125
Combination Product (Y/N)N
Initial Reporter CountryPO
PMA/510(K) Number
K980855
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Foreign,Health Professional,User Facility
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 06/26/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date09/30/2023
Device Model NumberN/A
Device Catalogue Number10380995
Device Lot Number365
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Follow-Up
Initial Date Received by Manufacturer 05/08/2023
Supplement Date Received by Manufacturer06/04/2023
Initial Report FDA Received Date06/02/2023
Supplement Report FDA Received Date06/26/2023
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured10/27/2022
Is the Device Labeled for Single Use? (Y/N) No
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient SexUnknown
-
-